Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00772785 · ClinicalTrials.gov registry record · Phase 3
Study of Probuphine in Patients With Opioid Dependence
A Phase 3 study, sponsored by Titan Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 16
- Enrollment target
NCT00772785 is a Phase 3 study that was terminated before completion, run by Titan Pharmaceuticals. The registered enrollment target is 16 participants.
The verdict
NCT00772785, a Phase 3 study, was terminated before completion, sponsored by Titan Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 16 participants
- Enrollment target
Study Summary
Buprenorphine (BPN) is an approved treatment for opioid dependence; however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine (buprenorphine implant) is an implant placed just beneath the skin that contains BPN. It is designed to provide 6 months of stable BPN blood levels. This study will test the safety and efficacy of Probuphine in the treatment of patients with opioid dependence. Patients who have completed at least 24 weeks of treatment in the Open-Label, Multi-Center Study of Probuphine in Patients with Opioid Dependence (PRO-807 Study), will be re-treated with Probuphine over an additional 24 weeks.
Interventions
- DRUG Probuphine (buprenorphine implant)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00772785
The ClinicalTrials.gov registry entry for NCT00772785 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Titan Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Probuphine (buprenorphine implant) is the first listed.
NCT00772785 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00772785 about?
NCT00772785 is a clinical study titled "Study of Probuphine in Patients With Opioid Dependence". Buprenorphine (BPN) is an approved treatment for opioid dependence; however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine (buprenorphine implant) is an implant placed just beneath the skin that contains BPN. It is d...
What is the current status of trial NCT00772785?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 16 participants. The study started on 2008-09. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00772785?
The interventions under investigation include: Probuphine (buprenorphine implant) (DRUG).
Who is sponsoring clinical trial NCT00772785?
This trial is sponsored by Titan Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.